Dermatology
Brief review: Nails in systemic disease.
12 Aug, 2021 | 08:40h | UTCNails in systemic disease – Clinical Medicine Journal
Brief review: Immunobullous disease.
12 Aug, 2021 | 08:37h | UTCImmunobullous disease – Clinical Medicine Journal
Psoriasis: a brief overview.
12 Aug, 2021 | 08:39h | UTCPsoriasis: a brief overview – Clinical Medicine Journal
Brief review: Advances in atopic dermatitis.
12 Aug, 2021 | 08:32h | UTCAdvances in atopic dermatitis – Clinical Medicine Journal
Cutaneous manifestations of infections: an update for general physicians.
12 Aug, 2021 | 08:36h | UTCCutaneous manifestations of infections: an update for general physicians – Clinical Medicine Journal
NICE Guideline | Management of Acne Vulgaris.
10 Aug, 2021 | 09:00h | UTCAcne vulgaris: management – National Institute for Health and Care Excellence
Evidence-based approach to nailbed injuries: ED presentations, evaluation, and management.
10 Aug, 2021 | 08:47h | UTCEvidence-based Approach to Nailbed Injuries: ED Presentations, Evaluation, and management – emDocs
Bullous autoimmune dermatoses: clinical features, diagnostic evaluation, and treatment options.
10 Aug, 2021 | 08:44h | UTCBullous Autoimmune Dermatoses – Deutsches Ärzteblatt International
Guideline summary: A Multidisciplinary collaborative approach to retinal toxic effects screening for patients taking antimalarials.
2 Aug, 2021 | 00:03h | UTCA Multidisciplinary Collaborative Approach to Retinal Toxic Effects Screening for Dermatology Patients Taking Antimalarials – JAMA Dermatology (free for a limited period)
Original Guidance: Joint Statement: Hydroxychloroquine use with respect to retinal toxicity
The use and impact of monoclonal antibody biologics during pregnancy.
28 Jul, 2021 | 09:43h | UTC
Podcast | Common Skin Complaints in Primary Care.
21 Jul, 2021 | 10:22h | UTC#285 Common Skin Complaints in Primary Care – The Curbsiders
2021 ACR Guideline for the Management of Polyarteritis Nodosa.
13 Jul, 2021 | 09:37h | UTC
Viewpoint | Active surveillance as a management option for low-risk basal cell carcinoma.
15 Jun, 2021 | 08:49h | UTC
COVID nails: these changes to your fingernails may show you’ve had coronavirus.
10 Jun, 2021 | 09:42h | UTCCOVID nails: these changes to your fingernails may show you’ve had coronavirus – The Conversation
COVID-19 Imaging: What we know now and what remains unknown.
9 Jun, 2021 | 08:27h | UTCCOVID-19 Imaging: What We Know Now and What Remains Unknown – Radiology
Practice Pointer | Mask related acne (“maskne”) and other facial dermatoses.
8 Jun, 2021 | 09:24h | UTCMask related acne (“maskne”) and other facial dermatoses – The BMJ
Commentary on Twitter
The term “maskne” has become increasingly popular during the pandemic, particularly in the media.
This #BMJInfographic presents common distributions that can be used as a starting point for assessment @will_s_t https://t.co/mKQUaN3PYY pic.twitter.com/OCBuFxiY9s
— The BMJ (@bmj_latest) June 7, 2021
Diagnostic value of cutaneous manifestation of SARS-CoV-2 infection – there was a significant association between skin rashes and a positive swab test result (odds ratio 1.67).
8 Jun, 2021 | 09:26h | UTCDiagnostic value of cutaneous manifestation of SARS-CoV-2 infection – British Journal of Dermatology
RCT: Among patients with pemphigus vulgaris, rituximab was superior to mycophenolate mofetil in producing sustained complete remission at 52 weeks (40% vs 10%) but was associated with increased risk of serious adverse events (22% vs. 15%).
24 May, 2021 | 08:24h | UTC
New Google AI tool can help patients identify common skin conditions.
24 May, 2021 | 08:23h | UTCUsing AI to help find answers to common skin conditions – Google
Commentary: Google AI tool can help patients identify skin conditions – BBC
Review: Histiocytosis
4 May, 2021 | 08:29h | UTC
New studies in patients with moderate-to-severe psoriasis show greater skin clearance with Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits both interleukin-17A and interleukin-17F
25 Apr, 2021 | 21:08h | UTCStudy 1: Bimekizumab versus Secukinumab in Plaque Psoriasis – New England Journal of Medicine
Study 2: Bimekizumab versus Adalimumab in Plaque Psoriasis – New England Journal of Medicine
Related studies: Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase trial – The Lancet AND Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial – The Lancet
RCT: Atenolol has similar efficacy as propranolol with fewer adverse events in the treatment of problematic infantile hemangiomas
20 Apr, 2021 | 05:32h | UTCEfficacy and Safety of Propranolol vs Atenolol in Infants With Problematic Infantile Hemangiomas: A Randomized Clinical Trial – JAMA Otolaryngology-Head & Neck Surgery (link to abstract – $ for full-text)
Cohort study: Higher cumulative exposure to Thiazide diuretics linked to an increased risk of skin cancer in people older than 65 years
13 Apr, 2021 | 05:08h | UTCCommentaries: Thiazides May Up Risk for Skin Cancer in Older Adults – HealthDay AND Some blood pressure medication linked to higher risk of skin cancer, study finds – CTV News
Related study: Case-Control Study: Possible Association of Hydrochlorothiazide Use and Risk of Melanoma
Diagnosis and management of leukocytoclastic vasculitis
14 Apr, 2021 | 01:26h | UTCDiagnosis and management of leukocytoclastic vasculitis – Internal and Emergency Medicine
Guidelines of care for the management of actinic keratosis
9 Apr, 2021 | 03:20h | UTC